Turning to the issue of which patents are Orange Book listable, the Federal Circuit dismissed Teva’s argument that these patents were properly listed because they covered the ProAir® HFA device.[19] ...
Dec 20 (Reuters) - Teva Pharmaceuticals (TEVA.TA), opens new tab failed to convince a U.S. appeals court on Friday to reverse a decision that would remove patents related to its ProAir HFA inhaler ...
On December 20, 2024, the US Court of Appeals for the Federal Circuit released its opinion in Teva Branded Pharm. Prods. R&D, Inc. v. Amneal Pharms. of N.Y., LLC, affirming a lower court decision that ...
June 10 (Reuters) - Drugmaker Amneal Pharmaceuticals (AMRX.O), opens new tab with the backing of the U.S. Federal Trade Commission convinced a New Jersey federal court on Monday to remove five Teva ...
After being called out on some intellectual property claims late last year, Teva has fallen victim to the Federal Trade Commission’s (FTC’s) ongoing crusade against questionable drug patents. This ...
Please provide your email address to receive an email when new articles are posted on . The ProAir Digihaler captured peak inspiratory flow, inhalation volume, inhalation duration, time to peak ...
While certain other drugmakers have relented in the face of the U.S. Federal Trade Commission’s (FTC’s) assault on alleged “junk” patents in the FDA’s Orange Book, Teva has largely stood its ground.
Hosted on MSN
Digital Inhaler May Predict Acute COPD Exacerbations
TUESDAY, July 1, 2025 (HealthDay News) -- Digital inhalers may help predict the occurrence of acute exacerbations of chronic obstructive pulmonary disease (COPD) for patients in an ambulatory setting, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback